Cite

HARVARD Citation

    Bhat, S. et al. (2022). Adalimumab-Adbm: The First Interchangeable Biosimilar for the Treatment of Inflammatory Diseases. Annals of pharmacotherapy. 56 (12), pp. 1356-1364. [Online]. 
  
Back to record